Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.
MetadataShow full item record
<h4>Purpose</h4>Metastatic colorectal cancers (mCRCs) assigned to the transit-amplifying (TA) CRCAssigner subtype are more sensitive to anti-epidermal growth factor receptor (EGFR) therapy. We evaluated the association between the intratumoral presence of TA signature (TA-high/TA-low, dubbed as TA-ness classification) and outcomes in CRCs treated with anti-EGFR therapy.<h4>Patients and methods</h4>The TA-ness classes were defined in a discovery cohort (n = 84) and independently validated in a clinical trial (CO.20; cetuximab monotherapy arm; n = 121) and other samples using an established NanoString-based gene expression assay. Progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) according to TA-ness classification were assessed by univariate and multivariate analyses.<h4>Results</h4>The TA-ness was measured in 772 samples from 712 patients. Patients (treated with anti-EGFR therapy) with TA-high tumors had significantly longer PFS (discovery hazard ratio [HR], 0.40; 95% CI, 0.25 to 0.64; <i>P</i> < .001; validation HR, 0.65; 95% CI, 0.45 to 0.93; <i>P</i> = .018), longer OS (discovery HR, 0.48; 95% CI, 0.29 to 0.78; <i>P</i> = .003; validation HR, 0.67; 95% CI, 0.46 to 0.98; <i>P</i> = .04), and higher DCR (discovery odds ratio [OR]; 14.8; 95% CI, 4.30 to 59.54; <i>P</i> < .001; validation OR, 4.35; 95% CI, 2.00 to 9.09; <i>P</i> < .001). TA-ness classification and its association with anti-EGFR therapy outcomes were further confirmed using publicly available data (n = 80) from metastatic samples (PFS <i>P</i> < .001) and patient-derived xenografts (<i>P</i> = .042). In an exploratory analysis of 55 patients with <i>RAS/BRAF</i> wild-type and left-sided tumors, TA-high class was significantly associated with longer PFS and trend toward higher response rate (PFS HR, 0.53; 95% CI, 0.28 to 1.00; <i>P</i> = .049; OR, 5.88; 95% CI, 0.71 to 4.55; <i>P</i> = .09; response rate 33% in TA-high and 7.7% in TA-low).<h4>Conclusion</h4>TA-ness classification is associated with prognosis in patients with mCRC treated with anti-EGFR therapy and may further help understanding the value of sidedness in patients with <i>RAS/BRAF</i> wild-type tumors.
Version of record
Genomic Analysis – Clinical Trials
Medicine (RMH Smith Cunningham)
Systems and Precision Cancer Medicine
License start date
JCO precision oncology, 2020, 4